Gallacher Capital Management LLC Purchases 2,291 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Gallacher Capital Management LLC boosted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 54.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 6,526 shares of the biopharmaceutical company’s stock after acquiring an additional 2,291 shares during the period. Gallacher Capital Management LLC’s holdings in Halozyme Therapeutics were worth $312,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Royce & Associates LP lifted its position in shares of Halozyme Therapeutics by 58.9% in the 4th quarter. Royce & Associates LP now owns 196,999 shares of the biopharmaceutical company’s stock worth $9,419,000 after purchasing an additional 72,988 shares during the period. CBIZ Investment Advisory Services LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $29,000. Aurora Investment Counsel lifted its position in shares of Halozyme Therapeutics by 8.6% in the 4th quarter. Aurora Investment Counsel now owns 35,118 shares of the biopharmaceutical company’s stock worth $1,679,000 after purchasing an additional 2,768 shares during the period. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $1,958,000. Finally, Avantax Advisory Services Inc. lifted its position in shares of Halozyme Therapeutics by 23.2% in the 4th quarter. Avantax Advisory Services Inc. now owns 9,766 shares of the biopharmaceutical company’s stock worth $467,000 after purchasing an additional 1,839 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insiders Place Their Bets

In other news, Director Jeffrey William Henderson sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $50.01, for a total value of $500,100.00. Following the completion of the sale, the director now directly owns 43,611 shares in the company, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Michael J. Labarre sold 1,697 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total transaction of $98,901.16. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at $10,126,499.68. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,697 shares of company stock valued at $1,754,451. Insiders own 2.40% of the company’s stock.

Analyst Upgrades and Downgrades

HALO has been the subject of several research analyst reports. Benchmark reaffirmed a “buy” rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, February 20th. Piper Sandler raised their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Finally, Wells Fargo & Company lowered their price target on shares of Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $62.78.

Halozyme Therapeutics Stock Up 2.0 %

Shares of Halozyme Therapeutics stock opened at $62.27 on Monday. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The stock has a market capitalization of $7.67 billion, a PE ratio of 18.15, a price-to-earnings-growth ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52-week low of $37.73 and a 52-week high of $65.53. The company has a 50-day simple moving average of $57.05 and a two-hundred day simple moving average of $54.63.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analysts’ expectations of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. On average, analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.